Search

Insulin secretion is regulated in multiple steps, and one of the main steps is in the endoplasmic reticulum (ER). Here, we show that UDP-glucose induces proinsulin ubiquitination by cereblon, and uridine binds and competes for proinsulin degradation and behaves as sustainable insulin secretagogue. Using insulin mutagenesis of neonatal diabetes variant-C43G and maturity-onset diabetes of the young 10 (MODY10) variant-R46Q, UDP-glucose:glycoprotein glucosyltransferase 1 (UGGT1) protects cereblon-dependent proinsulin ubiquitination in the ER. Cereblon is a ligand-inducible E3 ubiquitin ligase, and we found that UDP-glucose is the first identified endogenous proinsulin protein degrader. Uridine-containing compounds, such as uridine, UMP, UTP, and UDP-galactose, inhibit cereblon-dependent proinsulin degradation and stimulate insulin secretion from 3 to 24 h after administration in β-cell lines as well as mice. This late and long-term insulin secretion stimulation is designated a day sustainable insulin secretion stimulation. Uridine-containing compounds are designated as proinsulin degradation regulators.

We previously reported that glucokinase is ubiquitinated and degraded by cereblon with an unknown endogenous glucokinase protein degrader. Here, we show that UDP-glucose is a glucokinase protein degrader. We identified that both glucose and UDP-glucose bind to glucokinase and that both uridine and UDP-glucose bind to cereblon in a similar way to thalidomide. From these results, UDP-glucose was identified as a molecular glue between cereblon and glucokinase. Glucokinase produces glucose-6-phosphate in the pancreas and liver. Especially in β-cells, glucokinase is the main target of glucose for glucose-induced insulin secretion. UDP-glucose administration ubiquitinated and degraded glucokinase, lowered glucose-6-phosphate production, and then reduced insulin secretion in β-cell lines and mice. Maturity-onset diabetes of the young type 2 (MODY2) glucokinaseE256K mutant protein was resistant to UDP-glucose induced ubiquitination and degradation. Taken together, glucokinase ubiquitination and degradation signaling might be impaired in MODY2 patients.

Hydrogen boride (HB) sheets are emerging as a promising two-dimensional (2D) boron material, with potential applications as unique electrodes, substrates, and hydrogen storage materials. The 2D layered structure of HB was successfully synthesized using an ion-exchange method. The chemical bonding and structure of the HB sheets were investigated using Fourier Transform Infrared (FT–IR) spectroscopy and Transmission Electron Microscopy (TEM), respectively. X-ray photoelectron spectroscopy (XPS) was employed to study the chemical states and transformation of the components before and after atomic hydrogen adsorption, thereby elucidating the atomic hydrogen adsorption process on HB sheets. Our results indicate that, upon atomic hydrogen adsorption onto the HB sheets, the B-H-B bonds were broken and converted into B-H bonds. This research highlights and demonstrates the changes in chemical states and component transformations of the boron element on the HB sheets' surface before and after atomic hydrogen adsorption, thus providing a clearer understanding of the unique bonding and structural characteristics of the HB sheets. [ABSTRACT FROM AUTHOR]

BACKGROUND: Hip flexion angle-torque may not be measured accurately due to the measurement posture. OBJECTIVE: Maximum isometric hip flexion torque was measured while excluding the effects of postural retention function and compensatory motion. METHODS: Experiment 1: Maximum isometric flexion torque of the hip joint was measured at 0∘, 30∘, 60∘, 90∘, and 105∘ in 195 participants. Experiment 2: Maximum isometric hip flexion torque of 33 participants was measured in standing and supine position at 0∘ hip flexion and in end-sitting and supine position at 105∘. RESULTS: Experiment 1: No interaction was observed between sex and hip angle, and hip flexion torque was minimum at 0∘ hip flexion and maximum at 105∘ hip flexion in both sexes (p < 0.01). Experiment 2: An interaction between measurement position and hip angle was observed, with maximum isometric flexion torque being greater in the supine position than in the standing position (p < 0.01). Maximum isometric hip flexion torque was greater at 105∘ than at 0∘ flexion (p < 0.01). CONCLUSIONS: Maximum isometric hip flexion torque showed greater joint angle-torque characteristics in deep flexion than in shallow flexion of the hip when excluding the effects of postural retention function and compensatory motion. [ABSTRACT FROM AUTHOR]

To develop novel inorganic red pigments without harmful elements, we focused on the band structure of Ca2(Mg, Co)WO6 and attempted to narrow its bandgap by replacing the W6+ sites in the host structure of Mo6+. Ca2Mg1−xCoxW1−yMoyO6 (0.10 ≤ x ≤ 0.30; 0.45 ≤ y ≤ 0.60) samples were synthesized by a sol-gel method using citric acids, and the crystal structure, optical properties, and color of the samples were characterized. The Ca2Mg1−xCoxW1−yMoyO6 solid solution was successfully formed, which absorbed visible light at wavelengths below 600 nm. In addition, the absorption wavelength shifted to longer wavelengths with increasing Mo6+ content. This is because a new conduction band composed of a Co3d-W5d-Mo4d hybrid orbital was formed by Mo6+ doping to reduce the bandgap energy. Thus, the color of the samples gradually changed from pale orange to dark red, with a hue angle (h°) of less than 35°. Based on the above results, the optical absorption wavelength of the Ca2Mg1−xCoxW1−yMoyO6 system can be controlled to change the color by adjusting the bandgap energy. [ABSTRACT FROM AUTHOR]

The systemic treatment of psoriasis has changed markedly with the introduction of many novel drugs. However, clinicians have had limited opportunities to evaluate these new therapies. One of the new drugs, apremilast (a phosphodiesterase‐4 inhibitor), was approved in 2017 in Japan. We previously reported oral treatment for psoriasis before the introduction of apremilast. In this study, we investigated the impact of apremilast on oral medication for psoriasis by comparing data obtained before and after apremilast became available. This retrospective study enrolled patients who visited the Department of Dermatology, Fukuoka University Hospital, who were diagnosed with psoriasis and treated with anti‐psoriatic oral medications. Patients were divided into two groups: Group 1, who first visited our clinic between January 2010 and March 2016; and Group 2, who first visited our clinic between April 2016 and March 2022. The information collected included patient demographics, drug use (apremilast, cyclosporine, methotrexate, and etretinate), and treatment duration. In Group 1 (n = 149 patients), cyclosporine, methotrexate, and etretinate were prescribed to 59.1%, 16.6%, and 24.3% of the patients, respectively. In Group 2 (n = 129 patients), apremilast was prescribed to 52.5% of patients, while the number of prescriptions for cyclosporine and etretinate had decreased to 17.1% and 8.3%, respectively. The number of methotrexate prescriptions did not change significantly. Apremilast, methotrexate, and etretinate had longer continuation rates than cyclosporine in Group 2. In conclusion, apremilast replaced cyclosporine and etretinate mainly because of its better safety profile, whereas methotrexate remained in constant demand in both eras. New oral treatments for psoriasis, such as tyrosine kinase‐2 inhibitors, are now in the pipeline, and our data will serve as a control for oral anti‐psoriatic medicine before the coming era. [ABSTRACT FROM AUTHOR]